News

December 18, 2018

Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients

News

SELLAS Life Sciences announced plans for a newly streamlined Phase 3 trial to evaluate its investigational vaccine galinpepimut-S (GPS) as maintenance therapy for high-risk acute myeloid leukemia (AML) patients. If ... Read more

December 14, 2018

AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia

News

A Phase 1 clinical trial assessing Amgen’s immunotherapy AMG 330 showed promising results in acute myeloid leukemia (AML) patients who received at least one prior treatment, the company announced. AMG 330, given at 120 and 240 ... Read more

December 12, 2018

Imfinzi Falls Short in Prolonging Overall Survival of Metastatic NSCLC Patients, Phase 3 Trial Shows

News

Treatment with Imfinzi (durvalumab), with or without the investigational immunotherapy tremelimumab, failed to extend the survival of patients with metastatic non-small cell lung cancer (NSCLC) compared with standard chemotherapy in ... Read more

December 11, 2018

FDA Approves Tecentriq Combo as Initial Treatment for Select Patients with Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) and the chemotherapies Taxol (paclitaxel) and carboplatin, for a first-line treatment of certain patients with metastatic non-squamous ... Read more

December 7, 2018December 7, 2018

BioLineRx‘s Immunotherapy AGI-134 Receives FDA’s Biological Product Designation

News

The U.S. Food and Drug Administration has granted BioLineRx’s investigational immunotherapy AGI-134 a biological product designation, making the company eligible for 12-year market exclusivity after the treatment is approved in ... Read more

December 5, 2018December 5, 2018

Opdivo-Chemo Combo Doubles Survival Rates in Relapsed or Refractory Leukemia Patients, Phase 2 Trial Shows

News

A combination of Opdivo (nivolumab) and standard Vidaza (azacitidine) chemotherapy reduced the tumor burden in one-third of acute myeloid leukemia (AML) patients and doubled survival rates over patients treated with ... Read more

December 4, 2018

Yervoy, Local Injection of Candidate Therapy Tilsotolimod Shrink Advanced Melanoma Tumors, Trial Shows

News

A combination of Yervoy (ipilimumab) and Idera Pharmaceuticals’ investigational tilsotolimod reduced tumors in four out of 10 advanced melanoma patients included in a Phase 1/2 trial. Findings from the ILLUMINATE-204 trial (NCT02644967) were presented at the European ... Read more

November 30, 2018November 30, 2018

Tavo Reverses Resistance to PD-1 Inhibitors in Metastatic Melanoma, Phase 2b Trial Suggests

News

A combination of Tavo (tavokinogene telseplasmid/IL-12) and Keytruda (pembrolizumab) was effective at reducing tumors in advanced melanoma patients who had failed prior anti-PD-1 therapies, according to early results of a ... Read more

November 28, 2018

Opdivo Cancer Treatment Safe for HIV Patients on Antiretrovirals, Study Suggests

News

Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue taking antiretroviral therapies, a retrospective study shows. Findings ... Read more

November 27, 2018November 27, 2018

Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data Shows

News

A combination of Opdivo (nivoumab) and Yervoy (ipilimumab) significantly delayed the need for a subsequent treatment in patients with advanced or metastatic renal cell carcinoma who had not previously ... Read more

Pin It on Pinterest